Kozlowski M R, Arcuri M, Zynardi L
Department of Screening and Biochemical Research, Bristol-Myers Squibb Research Institute, Wallingford, CT 06492-7660.
J Recept Res. 1993;13(7):1031-40. doi: 10.3109/10799899309063262.
The effects of the angiotensin-II (AII) agonists and antagonists on both 125I-SARILE binding and phosphoinositol (PI) accumulation in clone 9 cells were examined. Clone 9 cells, which are derived from rat liver, have been shown to respond to AII agonists with an increase in PI accumulation which is inhibitable by Sar1,Ile8-AII (SARILE) and DUP-753 but not PD-123319, suggesting that they possess the AT1 subtype of AII receptor. The present results confirmed these properties. The order of potency of AII agonists was AII > AIII > AI. Clone 9 cells also possessed binding sites for 125I-SARILE. The majority of these were AT1 type receptors, although a small number of AT2 receptors may also have been present. The order of potency of AII agonists in inhibiting 125I-SARILE binding was AII >> AIII = AI. The difference in rank order of potency between the functional and binding assay was due to AIII being much less potent in the binding assay than the functional assay. Since the potency of AIII relative to AII was lower than that at either AT1 or AT2 subtypes of AII receptor, these data suggest that an additional subtype, with selectively low affinity for AIII, exists.
研究了血管紧张素 II(AII)激动剂和拮抗剂对克隆 9 细胞中 125I-SARILE 结合及磷酸肌醇(PI)积累的影响。克隆 9 细胞源自大鼠肝脏,已证明其对 AII 激动剂有反应,PI 积累增加,且可被 Sar1,Ile8-AII(SARILE)和 DUP-753 抑制,但不受 PD-123319 抑制,这表明它们具有 AII 受体的 AT1 亚型。目前的结果证实了这些特性。AII 激动剂的效力顺序为 AII > AIII > AI。克隆 9 细胞也具有 125I-SARILE 的结合位点。其中大多数是 AT1 型受体,尽管可能也存在少量的 AT2 受体。AII 激动剂抑制 125I-SARILE 结合的效力顺序为 AII >> AIII = AI。功能测定和结合测定中效力排序的差异是由于 AIII 在结合测定中的效力远低于功能测定。由于 AIII 相对于 AII 的效力低于 AII 受体的 AT1 或 AT2 亚型,这些数据表明存在一种对 AIII 具有选择性低亲和力的额外亚型。